This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Vanessa King, Ph.D.
CEO at Newco


Vanessa has spent the last two decades on the operating, deals and R&D side of pharma and biotech.  Vanessa comes to Virion from Luc Therapeutics, where, as President and CEO, she led the company’s transformation from single asset neuropsychiatry play to a precision medicine neuroscience company with a clinical pipeline.  Prior to that, she led business development in the founding leadership team for the restart of deCODE genetics, which was acquired by Amgen in 2012 for $415 million.  Vanessa has served as Chairman of Tiaki Therapeutics, been an Entrepreneur in Residence at Atlas Venture, and held senior business development and operating positions at Amgen and Novartis.  She earned her PhD in molecular genetics from the University of Cambridge.

Agenda Sessions

  • Company Building in Europe

  • Fireside Chat: Why on Earth be a CEO of a Biotech Company? A life of highs and lows.


Speakers at this event